meglumine has been researched along with Vomiting in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| AlObaidy, M; Altun, E; Burke, LM; Jeon, YH; Ramalho, M; Semelka, RC; Shin, KS; Stallings, CG | 1 |
| Ando, Y; Hayashi, T; Imaizumi, K; Isaji, A; Ito, K; Kawada, K; Matsuda, H; Mine, N; Miyamoto, A; Naito, K; Nakanishi, T; Okada, T; Oya, M; Sakurai, K; Shibata, T; Suzuki, E; Takahashi, H; Uyama, I; Yamada, S | 1 |
| Christensen, RE; Dillman, JR; Lai, ME; Mollard, BJ; Phan, T; Smith, EA | 1 |
| Bleicher, AG; Kanal, E | 1 |
| Durmus, T; Hamm, B; Heine, O; Maurer, M; Wagner, M; Wolf, M | 1 |
| Castillo, M; Hernandes, Mde A; Semelka, RC; Stallings, CG | 1 |
| Esfandiarpour, I; Farajzadeh, S; Fathabadi, EA; Heshmatkhah, A; Rahnama, Z | 1 |
| Corzo, JE; de la Rosa, R; Delgado, J; González-Moreno, MP; Leal, M; Lissen, E; Macías, J; Pineda, JA; Sánchez-Quijano, A | 1 |
3 trial(s) available for meglumine and Vomiting
| Article | Year |
|---|---|
Inter- and intra-individual comparative study of two gadolinium-based agents: A pilot study.
Topics: Aorta; Contrast Media; Double-Blind Method; Feasibility Studies; Female; Humans; Image Enhancement; Imaging, Three-Dimensional; Liver; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Observer Variation; Organometallic Compounds; Pancreas; Pilot Projects; Reproducibility of Results; Sensitivity and Specificity; Vomiting | 2015 |
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
Topics: Aged; Antiemetics; Aprepitant; Cisplatin; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Meglumine; Middle Aged; Morpholines; Nausea; Risk Factors; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome; Vomiting | 2016 |
Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child, Preschool; Contrast Media; Drug Eruptions; Female; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Organometallic Compounds; Pilot Projects; Reproducibility of Results; Sensitivity and Specificity; Single-Blind Method; Vomiting; Young Adult | 2013 |
5 other study(ies) available for meglumine and Vomiting
| Article | Year |
|---|---|
MR enterography under the age of 10 years: a single institutional experience.
Topics: Administration, Oral; Child; Child, Preschool; Contrast Media; Female; Humans; Infant; Infant, Newborn; Inflammatory Bowel Diseases; Magnetic Resonance Imaging; Male; Meglumine; Michigan; Nausea; Organometallic Compounds; Prevalence; Retrospective Studies; Risk Factors; Vomiting | 2016 |
Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine.
Topics: Contrast Media; Dyspnea; Humans; Magnetic Resonance Imaging; Meglumine; Nausea; Organometallic Compounds; Pennsylvania; Risk Assessment; Risk Factors; Urticaria; Vomiting | 2008 |
Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Comorbidity; Contrast Media; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nausea; Organometallic Compounds; Prevalence; Risk Assessment; Risk Factors; Urticaria; Vomiting; Young Adult | 2012 |
Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaphylaxis; Antiprotozoal Agents; Child; Child, Preschool; Cross-Sectional Studies; Erythema; Female; Humans; Infant; Injections, Intralesional; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pain; Pruritus; Treatment Outcome; Vomiting; Young Adult | 2012 |
High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Topics: Adult; Amylases; Animals; Antimony; Antiprotozoal Agents; Bone Marrow; Creatinine; Female; HIV Infections; HIV-1; Humans; Leishmania infantum; Leishmaniasis, Visceral; Leukocyte Count; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pancreatitis; Recurrence; Retrospective Studies; Vomiting | 1999 |